Financial research concept

Prescription Technology Solutions Operating Profit

Prescription Technology Solutions operating profit is McKesson's issuer-defined segment profit from medication-access technology, third-party logistics, and related services.

By Lee BaileyPublished Sep 24, 2026
Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date
Sep 24, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context
15 connected conceptsPart of the reviewed Healthcare Distribution & Services Economics; issuer definitions remain distinct where disclosed.
Company examples
1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
  1. Profit drivers
  2. What can distort it
  3. Part of the Healthcare Distribution & Services Economics
  4. See It in Company Research
  5. Continue Research

prescription technology solutions operating profit is McKesson's reported segment operating profit for Prescription Technology Solutions. McKesson reported fiscal 2026 Prescription Technology Solutions segment operating profit of $1.044 billion, up 19% from $875 million.

Profit drivers

Operating profit connects the segment's revenue to the costs and other items assigned to that business. Investors can use it to test whether revenue growth is translating into incremental segment earnings and whether mix shifts are improving or diluting economics.

What can distort it

Segment operating profit is an issuer-defined segment measure and is not the same as consolidated GAAP operating income. Read the dollar profit together with segment operating margin and the filing's reconciliation of unusual items before inferring underlying profitability.

Primary source: McKesson fiscal 2026 Form 10-K.

Part of the Healthcare Distribution & Services Economics

Connect pharmaceutical and medical distribution scale, specialty and prescription-technology profitability, service mix, and asset intensity to understand healthcare distribution and services economics.

How the model fits together
  • Core pharmaceutical distribution scale and margin: North American Pharmaceutical revenue shows the scale of McKesson's core distribution engine, while segment operating profit and margin show how a very large revenue base converts into segment earnings. Service revenue mix helps preserve the distinction between product-heavy distribution revenue and service-oriented economics.
  • Specialty care and prescription-technology economics: Oncology & Multispecialty and Prescription Technology Solutions pair revenue scale with segment profit and margin across specialty distribution, provider solutions, medication-access technology, and third-party logistics. Service revenue mix adds context for why these businesses can carry different economics without implying standardized peer margins.
  • Medical-surgical distribution and asset intensity: Medical-Surgical Solutions revenue, operating profit, and margin show the economics of non-acute distribution, while segment depreciation and amortization and long-lived-asset expenditures show different views of the asset base and current investment. Those capital measures are not interchangeable with each other or with total company capital expenditure.

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare healthcare distribution and services stocks

Continue into stock comparison after reviewing segment scale, profitability, service mix, and capital intensity across healthcare distribution and services businesses.

Continue research

Explore more topics in the Financial Research Encyclopedia.